Introduction
COVID-19, a coronavirus infection caused by SARS-CoV-2, has put a strain
on healthcare systems. The infection spreads quickly, and the lack of
universal testing and personal protective equipment have aggravated the
situation, as has the prevalence of silent infections. Because of the
vast number of COVID 19-infected individuals who present to various
hospitals, a thorough understanding of the clinical, radiographic, and
laboratory findings connected to higher severity of disease severity and
death is required. The identification of potential risk factors for
illness progression could be immensely valuable for healthcare personnel
in triaging patients, customizing treatment, monitoring clinical
progress, and allocating sufficient support at all levels to prevent
disease progress and death (1,2).
The SARS-CoV-2 characteristic of primary dormancy signs is another
element leading to the fast prevalence and dangerously large number of
affected patients. Fever with a quick start, coughing, and dyspnea are
the most prevalent symptoms of COVID-19. Pneumonia, renal failure,
bacterial superinfections, coagulation problems, and thrombosis are
complications. Several clinical and demographic variables, such as
advanced age, cardiovascular disease, and diabetes, are associated with
poor outcomes and higher risks of mortality. In more vulnerable
patients, such as infants, children, the elderly, and pregnant women,
this knowledge gap has an impact on infection risk, illness progression,
and outcomes. It is critical to understand better the risks of these
vulnerable patients to improve and personalize their treatment and
prevention techniques (2,3).
In terms of the extent of precautions and limits adopted by countries,
COVID-19 mortality and morbidity rates differ substantially. The
epidemiology of COVID-19 is substantially variable due to socio-cultural
or lifestyle disparities among residents, as well as disparities
in-country health policy. As a result, the fundamental causes of the
severe pandemic outbreak need to be elucidated and
we aimed to investigate the
impacts of demographic, hematological, and biochemical factors on the
clinical course and the prognostic outcome in adult COVID-19 patients.